Faculty Summaries
Suzanne M. Miller, PhD
Suzanne M. Miller, PhD
  • Director, Psychosocial and Biobehavioral Medicine Program
  • Professor, Cancer Prevention and Control Program
Office Phone: 215-728-4069
Lab Phone: 609-921-1297
Fax: 215-214-1651
Office: P4149
  • Lab Overview

    The overarching goal of Dr. Miller's lab is to make cancer prevention-control programs more effective by identifying the distinctive ways in which individuals make decisions, adjust to risk information, and manage recommended medical regimens. She employs a transdisciplinary team approach in designing, developing, and evaluating both traditional (e.g., print materials, telephone counseling) and new technology (e.g., text-messaging, web-based applications) interventions that are tailored to individual diffferences and targeted to group differences among patients and their families.

    Dr. Miller's work is based on her integrative theory-based framework, the Cognitive-Social Health Information Processing (C-SHIP) model, and focuses on interventions to enhance decision-making for prevention, treatment, and clinical trial options; adherence to recommended screening, prevention, and treatment regimens; adjustment to cancer risk feedback; and the translation and dissemination of interventions into clinical, community, and other service settings and systems.

    Dr. Miller's recent funded research has focused on developing and evaluating interventions designed to: 1) enhance decision making about preference-sensitive cancer screening and treatment options; 2) increase adherence to follow-up cervical cancer diagnostic screening following an abnormal Pap smear among inner-city women; 3) promote long term smoking cessation among underserved pregnant and postpartum women; (4) facilitate the transition from active treatment into survivorship to improve adaptation, self management, and surveillance, especially among low-health literacy populations; (5) facilitate information processing, high quality prevention and treatment decisions, and adaptation among women at risk for breast and ovarian cancer; and (6) improve informed consent procedures in both research and hospital contexts.